Loading…

Localization of the α-chemokine SDF-1 and its receptor CXCR4 in idiopathic inflammatory myopathies

We studied the distribution of stromal cell-derived factor 1 isoforms α and β, and their receptor CXCR4, in polymyositis, sporadic inclusion body myositis and dermatomyositis using in situ hybridization, immunohistochemistry, immunofluorescence and Western blotting. In control muscle, polymyositis a...

Full description

Saved in:
Bibliographic Details
Published in:Neuromuscular disorders : NMD 2004-04, Vol.14 (4), p.265-273
Main Authors: De Paepe, Boel, Schröder, J.Michael, Martin, Jean-Jacques, Racz, Gabor Z, De Bleecker, Jan L
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We studied the distribution of stromal cell-derived factor 1 isoforms α and β, and their receptor CXCR4, in polymyositis, sporadic inclusion body myositis and dermatomyositis using in situ hybridization, immunohistochemistry, immunofluorescence and Western blotting. In control muscle, polymyositis and sporadic inclusion body myositis, stromal cell-derived factor-1α expression was noted in muscle fibers, while stromal cell-derived factor-1β and CXCR4 were predominantly localized to capillaries and arterioles. In dermatomyositis, stromal cell-derived factor-1β immunoreactivity of blood vessels was focally increased. The vast majority of inflammatory cells in idiopathic inflammatory myopathies were CXCR4 positive. A subset of helper T-cells and macrophages expressed stromal cell-derived factor-1α, while only rare inflammatory cells expressed stromal cell-derived factor-1β. A significant increase of stromal cell-derived factor-1α and CXCR4 was observed in protein extracts of idiopathic inflammatory myopathies in comparison with normal controls. The abundance of both CXCR4 and its ligand stromal cell-derived factor-1 implicates their interaction in the pathogenesis of idiopathic inflammatory myopathies and identifies these proteins as possible targets for selective immune therapy.
ISSN:0960-8966
1873-2364
DOI:10.1016/j.nmd.2004.01.001